CASSAVA
Simufilam
Following initial Phase 3 clinical trials, this study extends our investigation into Simufilam‘s long-term efficacy for patients with Alzheimer’s disease. Participants continue to receive Simufilam to monitor ongoing effects on improving cognitive functions and slowing down Alzheimer’s disease progression.
Status: ACTIVE, NOT RECRUITING